SEC Form 3 · accession 0001358403-19-000028
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Aaron E. Foster
Officer — Sr VP, Head of Research
Period of report
Feb 11, 2019
Accepted (ET)
Feb 20, 2019 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 3,737 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.47 | holding | — | — | — | — | Oct 27, 2024 | Common Stock | 23,529 | — | D |
| Stock Option (right to buy)F2 | $23.47 | holding | — | — | — | — | Feb 23, 2025 | Common Stock | 8,000 | — | D |
| Stock Option (right to buy)F3 | $19.00 | holding | — | — | — | — | Jan 3, 2026 | Common Stock | 15,000 | — | D |
| Stock Option (right to buy)F4 | $12.39 | holding | — | — | — | — | May 31, 2026 | Common Stock | 30,000 | — | D |
| Stock Option (right to buy)F5 | $13.89 | holding | — | — | — | — | Jan 2, 2027 | Common Stock | 4,500 | — | D |
| Stock Option (right to buy)F6 | $11.70 | holding | — | — | — | — | Jul 2, 2027 | Common Stock | 10,500 | — | D |
| Stock Option (right to buy)F7 | $9.23 | holding | — | — | — | — | Jan 1, 2028 | Common Stock | 18,000 | — | D |
| Stock Option (right to buy)F8 | $7.72 | holding | — | — | — | — | Jul 1, 2028 | Common Stock | 42,000 | — | D |
| Stock Option (right to buy)F9 | $3.35 | holding | — | — | — | — | Jan 31, 2029 | Common Stock | 50,000 | — | D |
| Restricted Stock UnitsF11,F10 | — | holding | — | — | — | — | — | Common Stock | 1,250 | — | D |
| Restricted Stock UnitsF11,F12 | — | holding | — | — | — | — | — | Common Stock | 7,500 | — | D |
Explanation of responses
- F125% of the shares subject to the stock option vest and become exercisable on October 28, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- F10On January 3, 2017, the reporting person was granted restricted stock units (the "RSUs") for 2,500 shares. The RSUs vest in four annual installments beginning on January 3, 2018.
- F11Each RSU represents a contingent right to receive one share of the Issuer common stock.
- F12On January 2, 2018, the reporting person was granted the RSUs for 10,000 shares. The RSUs vest in four equal annual installments beginning on January 2, 2019.
- F225% of the shares subject to the stock option vest and become exercisable on February 24, 2016, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- F325% of the shares subject to the stock option vest and become exercisable on January 4, 2017, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- F425% of the shares subject to the stock option vest and become exercisable on June 1, 2017, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- F525% of the shares subject to the stock option vest and become exercisable on January 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- F625% of the shares subject to the stock option vest and become exercisable on July 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- F725% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- F825% of the shares subject to the stock option vest and become exercisable on July 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- F925% of the shares subject to the stock option vest and become exercisable on January 1, 2020, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
Remarks
EXHIBIT LIST: EX-24 power of attorney